# A Study of Trastuzumab Emtansine (Trastuzumab-MCC-DM1, T-DM1) in Combination With Pertuzumab Administered to Patients With Human Epidermal Growth Factor Receptor-2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer Who Have Previously Received Trastuzumab

> **NCT00875979** · PHASE1,PHASE2 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 67 (actual)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** Trastuzumab emtansine [Kadcyla] 3.0 mg/kg
- **DRUG:** Trastuzumab emtansine [Kadcyla] 3.6 mg/kg
- **DRUG:** Pertuzumab 420 mg

## Key facts

- **NCT ID:** NCT00875979
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-05
- **Primary completion:** 2011-08
- **Final completion:** 2011-08
- **Target enrollment:** 67 (ACTUAL)
- **Last updated:** 2013-12-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00875979

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00875979, "A Study of Trastuzumab Emtansine (Trastuzumab-MCC-DM1, T-DM1) in Combination With Pertuzumab Administered to Patients With Human Epidermal Growth Factor Receptor-2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer Who Have Previously Received Trastuzumab". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00875979. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*